Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide. Despite improvements in local therapies including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients who develop recurrence or present with advanced disease. Systemic therapy with the tyrosine kinase inhibitor sorafenib represents a milestone in advanced HCC, but provides a limited survival benefit. Ongoing efforts to study hepatocarcinogenesis have identified an important role of c-MET signaling in the promotion of tumor growth, angiogenesis, and metastasis. In this review, we summarize the preclinical data from human tissue, cell lines, and animal models that implicate c-MET in the pathogenesis of HCC. We also evaluate potential biomarkers that may estimate prognosis or predict response to c-MET inhibitors for more rational clinical trial design. Finally, we discuss the latest clinical trials of c-MET inhibitors in advanced HCC.
INTRODUCTION
Liver cancer ranks sixth in incidence and third in mortality among all cancers worldwide (1) . The most common primary liver cancer -hepatocellular carcinoma (HCC) -accounts for 70-85% of cases (2) .
Advanced HCC carries a poor prognosis with a five-year survival of <10% (3) . While chemotherapy has shown limited efficacy, two large randomized trials have demonstrated that the small molecule tyrosine kinase inhibitor (TKI) sorafenib (Nexavar ® , Bayer and Onyx) improves survival in advanced HCC compared to placebo, but the median overall survival remains less than one year (4) (5) (6) . As the search for novel and effective treatments continues, the TK receptor c-MET is emerging as a therapeutic target in HCC. In this review, we discuss the role of the c-MET pathway in hepatocarcinogenesis, summarize the preclinical data supporting its potential as a therapeutic target in HCC, and review the prognostic and predictive value of relevant biomarkers. Finally, we will provide an update on c-MET inhibitors currently under investigation in HCC.
THE HGF/c-MET PATHWAY
The c-MET proto-oncogene was originally identified as a fusion gene (tpr-met) in a chemically-transformed human osteosarcoma cell line (7) . It encodes for the receptor for the ligand hepatocyte growth factor (HGF) (8) . In the canonical HGF/c-MET signaling pathway, HGF binding leads to receptor homodimerization, autophosphorylation of tyrosine residues of the carboxy-terminal domain c-MET, and downstream activation of the MAPK, PI3K, and Rac1-Cdc42 pathways ( Figure 1 , reviewed in (9) ). c-MET phosphorylation in the absence of HGF can occur through interactions with the epidermal growth factor receptor (EGFR), cell attachment (10) , or binding of the alternate ligand des-gamma-carboxyprothrombin (11) . Regardless of the mode of activation, c-MET dimerization, autophosphorylation, and kinase activity appear to be necessary for malignant transformation (12) (13) (14) .
The HGF/c-MET axis has been shown to exert diverse physiologic effects on cell proliferation, survival, migration, and angiogenesis with important roles in liver development and regeneration. HGF acts as a potent mitogen for primary hepatocytes (15) and promotes cell motility of epithelial cells in vitro (16 endogenously overexpressed in the liver revealed both tumor-promoting and tumor-inhibiting effects of HGF (42) (43) (44) (45) . On the contrary, transgenic models of c-MET overexpression have consistently induced HCC formation in vivo. Liver-specific overexpression of c-MET in mice led to HCC formation in a ligandindependent fashion, and withdrawal of c-MET overexpression promoted marked tumor regression, suggesting a continued role of c-MET in tumor maintenance in vivo (10) . Moreover, overexpression of c-MET cooperated with other oncogenes characteristic of HCC -c-myc or mutant beta-catenin -to generate HCC with shorter latency and survival in mice (46, 47) . These data support the role of c-MET in HCC tumor progression and maintenance, providing a rationale for the clinical development of c-MET inhibitors for HCC.
Combined inhibition of HGF/c-MET and VEGF pathways in preclinical models
Several lines of evidence support a significant role of HGF/c-MET in promoting angiogenesis. First, HGF directly promoted the growth of endothelial cells both in vitro and in vivo (48) . Second, HGF induced VEGF and suppressed TSP1 (a negative regulator of angiogenesis) expression in cultured breast and leiomyosarcoma cells and in xenografts (49) . Third, transgenic mice overexpressing HGF exhibited increased angiogenesis and VEGF transcription in chemically-induced hepatic adenomas and HCC (43) .
Finally, recent work has revealed significant crosstalk between the HGF/c-MET and VEGF/VEGFR pathways with synergism in enhancing proliferation, cytoskeletal remodeling, and migration in endothelial cells (50) . Interestingly, tumor hypoxia, a potential consequence of angiogenesis inhibitors, such as sorafenib, led to increased c-MET expression and potentiated the effect of HGF on c-MET activation, cell migration, and invasiveness (51) . Table 1 summarizes our current understanding of HGF and c-MET as biomarkers in HCC. Whereas tissue HGF levels have provided little/no prognostic information, plasma HGF levels were consistently higher in patients with HCC compared to normal subjects (26, 56, 57) . Moreover, circulating HGF levels correlated with decreased overall survival in untreated patients (56) and with increased tumor size, grade, recurrence, metastasis, post-operative complications, and worse overall survival after partial hepatectomy (26, 57) . A recent biomarker analysis of samples from the pivotal phase III trial of sorafenib showed a trend towards improved survival in patients with lower pre-treatment plasma HGF concentration (58) . There are two major caveats that limit the prognostic value of c-MET overexpression in HCC. First, the available data are primarily derived from patients with early-stage disease who have undergone partial hepatectomy (28, 31) , and the prognostic value of c-MET overexpression has not been definitively evaluated in advanced HCC. Second, the optimal method for evaluating c-MET protein expression remains controversial. One study performed densitometric analysis on western blots of tumor tissue using a median cutoff value to delineate high-versus low-c-MET expressing tumors. Five-year survival was significantly lower in the patients with high compared to low c-MET expression (33.5% and 80.3%, respectively) (30).
HGF AND c-MET AS BIOMARKERS IN HCC
Another study assessed c-MET expression in tumor tissue by immunohistochemistry (IHC) and showed shortened disease-free survival of patients with c-MET expression versus those without c-MET expression (60) . c-MET overexpression assessed by IHC in tumor tissue is the only predictive biomarker that has gained supportive evidence in early-phase trials of HGF/c-MET inhibitors (see below) (62) . However, the reproducibility and standardization of these approaches to assess c-MET expression need to be addressed in future studies as has been done previously for HER2 evaluation in breast cancer (63) . 
CLINICAL EXPERIENCE

Clinical trials of single agent c-MET inhibitors
In an effort to bring scientific knowledge from the bench to the bedside, several anti-c-MET agents are currently under development and can be broadly categorized into three groups: selective c-MET TKIs, (Table 2) .
Below we discuss the unpublished data from conference abstracts that present the clinical experience with these drugs.
Foretinib
Foretinib was the first c-MET TKI to be evaluated in clinical trials. It has a broad TKI spectrum, which includes c-MET and VEGFR. Foretinib was tested in a Phase I/II trial as first-line therapy for Asian patients with advanced HCC and Child-Pugh A cirrhosis or no cirrhosis. In the 38 of 39 patients treated at the MTD of 30 mg daily and evaluable for efficacy, foretinib exhibited an objective response rate (ORR) of 24%, disease control rate (DCR) of 79%, median time-to-progression (TTP) of 4.2 months, and median overall survival (OS) of 15.7 months. Foretinib had an acceptable toxicity profile, as the most common adverse events (AEs) were hypertension (36%), anorexia (23%), and fever (21%), and the most common serious adverse events (SAEs) were hepatic encephalopathy (10%) and ascites (8%) (64) .
Cabozantinib
Cabozantinib is an oral small molecule multi-targeted TKI with activity against c-MET, VEGFR2, and RET. In a Phase II randomized discontinuation trial, 41 patients with advanced HCC and Child-Pugh A cirrhosis received cabozantinib 100 mg daily for 12 weeks during a lead-in phase. Patients who had a partial response (PR) were maintained on open-label cabozantinib, while patients with stable disease were randomized to cabozantinib versus placebo. Patients with progressive disease (PD) discontinued treatment.
Two of 36 patients with evaluable disease at 12 weeks had a PR (6%), and a third patient randomized at 12 weeks achieved a PR at 18 weeks. The DCR at week 12 was 68%. A reduction in alpha-fetoprotein (AFP) by greater than 50% from baseline was seen in 26 patients. The median progression-free survival (PFS) was 4.4 months and OS was 15.1 months. Of note, the PFS was similar in patients who were sorafenib naïve (PFS 4.2 months, n=20) and who had prior sorafenib (PFS 5.2 months, n=21). The toxicity profile was acceptable; the most common Grade 3/4 AEs were diarrhea (17%), palmar-plantar erythrodysesthesia (PPE, 15%), and thrombocytopenia (10%) (65) . (66) . The drug then underwent Phase II testing in a randomized, placebo-controlled, multi-national, crossover trial of 107 patients with unresectable HCC who had failed one systemic therapy and had either no cirrhosis or Child-Pugh A cirrhosis (62) . Patients were randomized in a 2:1 fashion to tivantinib or placebo. Tivantinib was initially given at 360 mg BID but was changed to 240 mg BID due to a high incidence of neutropenia. The study met its primary endpoint with a modest improvement in TTP in the intent-to-treat population from 1.4 months to 1.6 months (HR=0.64, p=0.04), favoring the tivantinib group. The safety profile was acceptable with the most frequent drug-related AEs in the tivantinib group being neutropenia (25.4%) and anemia (15.5%). Grade 3-4 neutropenia was seen in 21% of patients at the 360 mg PO BID dose and 6% of patients at the 240 mg PO BID dose, so the latter dose was favored.
The most compelling data from this trial came from a subgroup analysis based on tumor c-MET expression.
Positive c-MET expression (≥2+ staining intensity in ≥50% of tumor cells by IHC) was associated with improved OS (3.8 vs. 7.2 months, HR=0.38, p=0.01), PFS (1.5 vs. 2.4 months, HR=0.45, p=0.02), and TTP (1.5 vs. 2.9 months, HR=0.43, p=0.03) (62) . Despite the early promising results with tivantinib in HCC, it should be cautioned that the sample size was small, the positive signal remained modest, and the data were based on a subgroup analysis (22 patients in the tivantinib arm and 15 patients in placebo arm for the c-MET high group). Currently, a phase III randomized trial comparing tivantinib 240 mg BID to placebo in patients with c-MET-positive advanced HCC in the second line setting is being planned.
Combination of c-MET inhibition with sorafenib
Based on preclinical data showing the synergy of tivantinib and sorafenib in multiple cell lines (52) AEs being rash (40%), PPE (35%), fatigue and diarrhea (30% each), and nausea and anorexia (25% each).
Neutropenia was reported in two patients (67) . These data along with the preliminary phase II results of foretinib and cabozantinib support the further development of combined c-MET and VEGF pathway inhibition in HCC.
FUTURE DEVELOPMENT OF c-MET INHIBITORS IN HCC
The recent failure of several phase III trials with VEGFR TKIs highlights the challenge and need for 
assess phospho-c-MET inhibition as a pharmacodynamic biomarker should be included in the study design.
Despite the rationale, interesting preclinical data of combined c-MET and VEGFR inhibition, and preliminary clinical data on foretinib and cabozantinib, the relative contribution of c-MET and VEGFR inhibition remains to be dissected. Finally, the successful development of c-MET inhibitors will rely on carefully designed clinical trials with adequate endpoint selection, correct target population, optimal assessment of clinical efficacy, and robust biomarker discovery as previously recommended (68) . Despite these challenges, nearly thirty years after its initial discovery, c-MET is emerging as a biologically rational and druggable target in HCC.
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